Mumbai, Feb 18 (PTI) NYSE-listed Boston ScientificCorporation today announced its launch of two drug-elutingstent in India.
Both stents incorporate platinum chromium (PtCr)alloy, innovative design and advanced catheter deliverysystem, and represent the company�s third-generationdrug-eluting stent (DES) technology, a company statement saidhere.
India is one of the fastest-growing DES markets in theworld, with the number of coronary drug-eluting stents (DES)implanted annually estimated at more than 150,000.
In 2010, the Company received approval from the DrugsController General of India to market the Element Systems.
"The Promus and Taxus Element Stent Systems givephysicians in India a choice of two proven drug and polymercombinations � used in millions of patients worldwide � on anentirely new platform," said Hank Kucheman, Executive VicePresident and Group President, Cardiology, Rhythm and Vascularfor Boston Scientific.